Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764531 | 0.81 | HRH4 (0.36) | ALDH1A1HTR1B | |
| SCHEMBL1764060 | 0.77 | — | — | |
| SCHEMBL291612 | 0.74 | — | — | |
| SCHEMBL29317119 | 0.72 | NOS3 (0.40) | HIF1A | |
| SCHEMBL21743144 | 0.72 | KDM4E (0.33) | ALDH1A1KDM4EHSD17B10HIF1A | |
| SCHEMBL12304218 | 0.72 | HPGD (0.50) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL28929855 | 0.69 | — | — | |
| SCHEMBL1763335 | 0.69 | — | — | |
| SCHEMBL29199445 | 0.69 | VHL (0.45) | ALDH1A1 | |
| SCHEMBL13732067 | 0.69 | NPSR1 (0.55) | ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-1444201-B1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-7179835-B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-20 | — | — | US | disclosed |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | PARP1 244/4885BCHE 4880/4885ACHE 4883/4885 |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | SERPINC1, F11, SERPINE1 | PARP1 898/4885BCHE 1178/4885ACHE 469/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | PARP1 1909/4885BCHE 1394/4885ACHE 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.